Life Sciences Companies divorce agrochem operations - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • Jul 14, 2000 - Life Sciences Companies divorce agrochem operations

Life Sciences Companies divorce agrochem operations

Jul 14, 2000

The wheel seems to have come a full circle for life science companies. The last year has seen an across the board spin off of their agro–chemical arms by the life science (a euphemism for a conglomerate of pharmaceutical and agrochemical operations) corporations. Novartis (formed with the merger of Ciba and Sandoz) de–merged its agro chemical arm and proposed a merger with Zeneca (the agro–chemical arm of Astra–Zeneca) to form Syngenta. Aventis Crop Science came into being with the merger of the agro–chemical arms of Hoechst Marion Roussel and Rhone Poulenc. Then American Home Products announced the sale of its agro–chemical business Cyanamid to the German specialty chemical conglomerate BASF.

Why has this happened? Why have international pharmaceutical majors gone back to the core competence mantra? Till the last year it was the pharmaceutical operations of the life science corporations, which were supposed to finance the biotech revolution. What has changed?

The answers were provided by Mr. Edward Schillinger, Managing Director, Novartis India at last week’s analysts meet. He said that there were two reasons for these developments. First, was the realisation, among life science companies, that there were hardly any synergies between the pharmaceutical operations and the agrochemical operations of the life science companies. The two catered to totally different markets and the type of personnel running the two operations were different. It was equivalent to running two businesses under the aegis of one company.

The second reason for the hive off was the pressure from the shareholders. This was due to the fact that last year was a bad year for the agrochemical business. (Even otherwise the returns from the pharmaceutical business are relatively higher than the agrochemical business.) Hence it was imperative that the shareholders interested in the pharmaceutical business were not deprived of their returns, which were otherwise getting averaged out by the lower returns from the agrochemical operations.

This would however imply that agro–chemical firms will have to fund their forays into biotech, gentology and tissue culture on their own. Mr. Schillinger, however clarified that the agrochemical businesses were not unviable businesses. These were sound businesses, which could very well finance their ambitious plans.

Infact, after the recent round of restructuring there would be around five firms, the world over which would dominate the agrochemical business. These include Monsanto (which ironically has proposed a merger with pharma major Pharmacia & Upjohn), Aventis Crop Science, Syngenta, Bayer and BASF–Cyanamid.

Equitymaster requests your view! Post a comment on "Life Sciences Companies divorce agrochem operations". Click here!


More Views on News

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market (Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing. (Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 1, 2021 (Close)